StockData
Design Therapeutics, Inc. logo

Design Therapeutics, Inc. (DSGN) stock

DSGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$9.84−0.08 (-0.81%)

Close on Nov 17, 2026Market cap $615.80MP/E –Yield –

Design Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Design Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$55.08M. For fiscal 2025 it was -$54.36M. The highest annual figure on record is -$8.67M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$54.36M–
FY2024Dec 31, 2024-$43.11M–
FY2023Dec 31, 2023-$58.56M–
FY2022Dec 31, 2022-$51.32M–
FY2021Dec 31, 2021-$29.38M–
FY2020Dec 31, 2020-$8.67M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$15.52M–
Q1 FY2026Mar 31, 2026-$16.43M–
Q4 FY2025Dec 31, 2025-$11.97M–
Q3 FY2025Sep 30, 2025-$11.16M–
Q2 FY2025Jun 30, 2025-$14.44M–
Q1 FY2025Mar 31, 2025-$16.79M–
Q4 FY2024Dec 31, 2024-$9.86M–
Q3 FY2024Sep 30, 2024-$9.55M–
Q2 FY2024Jun 30, 2024-$11.26M–
Q1 FY2024Mar 31, 2024-$12.44M–
Q4 FY2023Dec 31, 2023-$12.80M–
Q3 FY2023Sep 30, 2023-$14.53M–
Q2 FY2023Jun 30, 2023-$13.80M–
Q1 FY2023Mar 31, 2023-$17.42M–
Q4 FY2022Dec 31, 2022-$15.09M–
Q3 FY2022Sep 30, 2022-$13.90M–
Q2 FY2022Jun 30, 2022-$10.50M–
Q1 FY2022Mar 31, 2022-$11.83M–
Q4 FY2021Dec 31, 2021-$9.23M–
Q3 FY2021Sep 30, 2021-$8.16M–
Q2 FY2021Jun 30, 2021-$8.29M–
Q1 FY2021Mar 31, 2021-$3.70M–
Q4 FY2020Dec 31, 2020-$2.84M–
Q3 FY2020Sep 30, 2020-$1.86M–
Q2 FY2020Jun 30, 2020-$1.31M–
Q1 FY2020Mar 31, 2020-$2.66M–

More Design Therapeutics figures

See a number that looks wrong?